Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 621.01M |
| Revenue (ttm) | 13.24M |
| Net Income (ttm) | -81.25M |
| Shares Out | 35.75M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,277 |
| Open | 17.70 |
| Previous Close | 17.66 |
| Day's Range | 17.10 - 18.07 |
| 52-Week Range | 16.08 - 43.92 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.33 (+197.0%) |
| Est. Earnings Date | Nov 9, 2021 |
About PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also deve...
Financial Performance
In 2020, PLRX's revenue was $41.82 million, a decrease of -26.70% compared to the previous year's $57.05 million. Losses were -$41.53 million, 6,482.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 51.33, which is an increase of 197.05% from the latest price.
News
Pliant Therapeutics to Participate in Piper Sandler Lung Day
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...
Why Pliant Therapeutics Stock Is Surging Today
A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up.
Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 i...
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics fo...
Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
- PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Ph...
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies...
Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies ...
Pliant Therapeutics: An Early Stage Company With Important Collaborations
PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel ther...
Pliant Therapeutics to Present Data at The Liver Meeting® 2020
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...
Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020
SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
Could This Recent IPO Biotech Become the Next Moderna?
There's a chance that it could become an even bigger success story.
Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional S...
SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...
Pliant Therapeutics Shares Have Climbed 44% Since This Week’s IPO
Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.
Pliant Therapeutics Up 33% on IPO Pricing
Investors are excited about the biotech's prospects, but the company still has a long road ahead.
Pliant Therapeutics shares soar 55% in trading debut
Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.